Vardenafil 20 Mg

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nelfinavirnelfinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil contact info for adverse events reporting.
• It is one of several PDE5 inhibitors on the market.
• The medication requires sexual arousal to be effective.
• Take Vardenafil approximately 30 minutes before intimacy.
• Do not share your medication with others.
• Ensure proper hydration to help with absorption.
• The half-life of Vardenafil is around 4-5 hours.
• Do not use Vardenafil if you have had recent stroke or MI.
• Inform your doctor about all health conditions before use.
• Use Vardenafil responsibly to prevent dependency.
• Follow prescribed dosage for optimal results.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nelfinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Generic vs Brand

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors mirtazapinemirtazapine and vardenafil both increase QTc interval. mirtazapine and vardenafil both vardenafil vilitra 60 mg increase QTc interval. mitapivatmitapivat decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for loss of therapeutic effect of sensitive CYP3A substrates with narrow therapeutic index when coadministered with mitapivat. mitapivat decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Authors and Affiliations

mitotanemitotane decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments. mitotane decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nefazodonenefazodone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nefazodone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors netupitant/palonosetronnetupitant/palonosetron will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors netupitant/palonosetron will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Conflict of interest statement

itraconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ivacaftorivacaftor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ivacaftor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ketoconazoleketoconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ketoconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

4.3 Comparison with Other PDE5 Inhibitors and Formulations

lapatiniblapatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors lapatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors larotrectiniblarotrectinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors larotrectinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to tadalista professional be reduced if coadministered with moderate or strong CYP3A4 inhibitors lenacapavirlenacapavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Our Services

Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates. lenacapavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Limit vardenafil dose to 2.5 mg/24 lithiumlithium and vardenafil both increase QTc interval. lithium and vardenafil both increase QTc interval. lonafarniblonafarnib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nevirapinenevirapine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil enhances blood flow to the penis.
• It is sold under brand names like Levitra and Staxyn.
• The drug is generally well-tolerated when used correctly.
• Common side effects include dizziness and nasal congestion.
• It should be stored in a cool, dry place away from children.
• Vardenafil is not an aphrodisiac; it requires sexual stimulation.
• Excessive doses can increase cardiovascular risks.
• It’s important to follow the doctor’s instructions for use.
• Patients with heart conditions should consult a doctor before use.
• Vardenafil may cause visual disturbances in some people.
• Regular medical review is recommended during treatment.

nevirapine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipinenifedipine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

This article is cited by

If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling. lonafarnib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lopinavirlopinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors lopinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors lumefantrinelumefantrine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Report Problems to the Food and Drug Administration

lumefantrine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mavorixaformavorixafor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor QTc during treatment in patients with risk factors for QTc prolongation (eg, coadministered medications that increase mavorixafor exposure or other drugs with a high risk to prolong the QTc interval). Mavorixafor dose reduction or discontinuation may be required. mavorixafor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Less common

Monitor for adverse effects of sensitive CYP3A4 substrates if coadministered with mavorixafor (a weak CYP3A4 inhibitor). methylprednisolone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. metronidazolemetronidazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors metronidazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors Use alternatives if available.mifepristone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

nilotinibnilotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

LinkOut - more resources

hydroxyzine and vardenafil both increase QTc interval. ibrexafungerpibrexafungerp will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors imatinibimatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors imatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.

“Doc, if it were you, what would you do?”: a survey of Men’s Health specialists’ personal preferences regarding treatment modalities

Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors isavuconazonium sulfate will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors isoniazidisoniazid will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors isoniazid will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors istradefyllineistradefylline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Subscribe to MedicineNet's Men's Health Newsletter

Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates. istradefylline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. itraconazoleitraconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.